The global immunohistochemistry (IHC) market size was valued at approximately USD 2.40 billion in 2024 and is anticipated to grow to around USD 3.50 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.93% during the forecast period from 2025 to 2030. This upward trajectory is largely attributed to the growing integration of automation technologies and machine learning applications in IHC processes. Furthermore, the consistent launch of technologically sophisticated IHC solutions is anticipated to be a primary factor propelling the market forward throughout the coming years.Significant improvements in IHC protocols have notably increased their utilization in disease diagnosis. Alongside this, a surge in product approvals and the introduction of advanced immunohistochemistry systems have contributed to the expansion of the market. Supporting this development, many companies are continuously striving to introduce innovative platforms that match current technological standards while meeting the evolving demands of end-users.
Order a free sample PDF of the Immunohistochemistry Market Intelligence Study, published by Grand View Research.
Key Market Trends & Insights
1) In 2024, the antibodies segment accounted for the largest revenue share at 41.4%. This dominance is primarily due to the fundamental role antibodies play in disease diagnostics and drug testing. The market has seen an increased demand for monoclonal antibodies and related products such as Fc-fusion proteins, antibody fragments, and antibody-drug conjugates. These are widely adopted in fields like pathology, neuropathology, and hematopathology, positioning antibodies as a critical component in IHC-related applications.
2) The diagnostics segment held the leading position in the market with a revenue share exceeding 68.6% in 2024 and is expected to maintain this dominance through the forecast period. IHC testing is a vital component in diagnosing numerous chronic conditions such as cancer, cardiovascular diseases, infectious diseases, autoimmune disorders, diabetes, and kidney-related ailments, thereby driving demand in this segment.